GLOW (BPC-157 + TB-500 + GHK-Cu)

Compound Profile

GLOW (BPC-157 + TB-500 + GHK-Cu) is reviewed here for multi-compound formulation context.

Research Summary

Evidence Strength Very limited

Primary Evidence

Safety notices, literature searches, limited protocol data

Research Focus

Blend logic, Compatibility, Safety context

Mechanism

Target context: VEGFR2; G-Actin; MMP

Long-Term Data

Limited, unclear, or affected by safety flags.

Current Consensus

Claims need extra caution because evidence is thin or safety flags apply.

Route(s) Subcutaneous

Typical dose 2.8mg

Dosing window Anytime

Receptor / target VEGFR2; G-Actin; MMP

Properties Dopamine Buffer

Pre-mixed No

How GLOW (BPC-157 + TB-500 + GHK-Cu) works in the body

Protocols

Protocol logic check

Medical literature and study context

Independent evidence

Regulatory status: not approved multi compound blend component warnings

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

• Active cancer: BPC-157's potent angiogenic (VEGFR2-mediated) activity and GHK-Cu's comprehensive pro-growth gene program upregulation are both directly contraindicated in the context of active malignancy; tumor angiogenesis (the growth of new blood vessels into tumor tissue, upon which solid tumor growth above 1-2mm depends) would be accelerated by BPC-157's VEGFR2 stimulation; GHK-Cu's upregulation of collagen production, cell proliferation, and growth factor signaling could support tumor stroma formation and growth; absolute contraindication.
• Zinc deficiency (serum zinc below reference range): GHK-Cu is a copper-supplying compound; copper and zinc compete for intestinal absorption through shared ZIP/ZnT transporter systems (Menkes-Wilson competitive transport); daily GHK-Cu administration progressively depletes zinc by outcompeting zinc for intestinal absorption and increasing metallothionein-mediated zinc sequestration; zinc deficiency at baseline is a contraindication to initiating GLOW; zinc status should be confirmed and repleted before starting any GLOW cycle, and zinc supplementation (15-30mg/day zinc bisglycinate or zinc picolinate) is required throughout all GLOW cycles.
• Wilson's disease (copper metabolism disorder): Wilson's disease causes pathological copper accumulation due to defective ATP7B copper exporter function; GHK-Cu's copper delivery is absolutely contraindicated in Wilson's disease.
• Active inflammatory bowel disease in severe flare: while BPC-157 has mucosal protective effects in IBD, the high-dose GHK-Cu component's copper delivery in the context of the compromised gut mucosa and altered metal absorption of severe IBD flares is not characterized; GLOW is appropriate for remission maintenance and does not cover acute severe flare management.
• Concurrent copper-supplementing medications or multi-mineral supplements with high copper content: additive copper load from exogenous copper sources during a GLOW cycle could exceed safe copper accumulation thresholds; total daily copper intake across all sources should be monitored.
• Known hypersensitivity to BPC-157 (pentadecapeptide), TB-500 (thymosin beta-4 fragment), GHK-Cu (copper tripeptide), or formulation excipients.
• Severe hepatic impairment: the liver is the primary organ for copper processing and biliary copper excretion; compromised hepatic copper handling in cirrhosis or severe hepatic disease could lead to copper accumulation even with the 5-days-on protocol.
• Pregnancy: the combined angiogenic, matrix remodeling, and copper-delivering activity of GLOW during pregnancy has not been evaluated; both BPC-157 and GHK-Cu have effects on vascular and connective tissue remodeling that overlap with the highly active vascular and matrix changes of normal pregnancy.
• History of copper toxicity (symptoms of nausea, vomiting, abdominal pain, elevated LFTs from previous copper exposure): previous sensitivity to copper loading suggests heightened risk of accumulation on the GLOW copper load.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

• Injection site pain (PIP): even within the blended formulation, GHK-Cu contributes some degree of injection site pain beyond standard peptide injections; typically manageable and significantly reduced versus standalone GHK-Cu at equivalent doses; the GLOW blend formulation's primary design purpose is to mitigate this effect.
• Lethargy and sedation following injection: primarily attributable to the BPC-157 and TB-500 components; the mechanism is dopaminergic modulation; typically mild and lasting 1-3 hours post-injection; the "Dopamine Buffer" property tag reflects this CNS dopamine system interaction.
• Zinc depletion: the most important monitoring parameter; progressive zinc depletion from GHK-Cu copper competition occurs across all GLOW cycles; manifestations include impaired immune function, hair thinning, delayed wound healing, and taste/smell changes; zinc supplementation is essential.
• Mild copper accumulation symptoms: at doses approaching toxicity (unlikely at standard GLOW protocol doses with the 5-days-on schedule, but possible with protocol violations): nausea, vomiting, metallic taste, abdominal discomfort; the 5-days-on/2-days-off and 8-12 week cycle limit prevent clinically significant copper accumulation at standard doses.
• Mild headache: occasionally reported in the first 1-2 weeks of a GLOW cycle; mechanism unclear but possibly related to the hemodynamic effects of BPC-157's NO-synthase activity and vascular changes.
• Elevated liver enzymes (ALT/AST): mild transient LFT elevation occasionally observed during GLOW cycles, particularly at the 2.0mg GHK-Cu daily dose; related to hepatic copper processing load; typically resolves with cycle cessation and washout; warrants monitoring in subjects with pre-existing liver conditions.
• Temporary increase in existing inflammation signals: as the repair cascade activates, the initial phase can produce transient mild increases in local inflammation before anti-inflammatory and repair phases predominate; most notable in subjects using GLOW for acute injury management.
• Anhedonia (rare): occasionally reported with the BPC-157/TB-500 combination; related to the dopaminergic modulation mechanism of BPC-157; typically mild and transient.

Compatibility

The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• FDA drug/regulatory guidance
• FDA bulk-substance safety risk page
• PubMed literature search: GLOW (BPC-157 TB-500 GHK-Cu)
• ClinicalTrials.gov study records: GLOW (BPC-157 TB-500 GHK-Cu)
• NIH Office of Dietary Supplements fact sheet
• PubMed literature search: BPC-157
• PubMed literature search: thymosin beta 4
• PubMed literature search: GHK-Cu